RFA-CA-16-014 – Cancer Target Discovery and Development Network (U01)
LOI: 30 days prior to application due date
Internal Deadline: August 17, 2016, 5pm
External Deadline: October 3, 2016, 5pm PDT
Type: Cooperative Agreement
Estimated Number of Awards: 12
Anticipated Amount: $12 million in total.
Cost Sharing: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants
Materials to submit:
- Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt.).
- CV – (5 pages maximum)
Who May Serve as PI: Standard NIH requirements.
The CTD^2 FOA solicits applications for research projects focused on identifying and understanding: pathways that influence cancer phenotypes (including understanding the function of the genes/targets which are essential in cancer transformation and maintenance); perturbagens that can modulate such pathways; and biomarkers predicting responses to treatments, prognosis, and/or other aspects of cancer etiology that need to be understood in order to develop effective treatments in the future.
Research projects proposed in response to this FOA must combine informatics and complementary experimental approaches. These combined endeavors should aim to identify a) potential therapeutic targets and validate their relevance; and/or b) to develop probes or perturbagens for pathways that are important in the etiology of cancers and c) also address if the results are dependent on the defined genetic background (either germline or somatic) of the patient.
Where appropriate, informatics should be combined with high throughput assays in experiments designed to demonstrate that affecting identified targets can lead to the desirable outcomes such as the abrogation of the cancerous phenotype, the reduction of metastatic potential, and/or selective eradication of cancer cells even for heterogeneous tumors. Informatics may also facilitate the development of probes that specifically affect the function of the prospective targets and other experimental approaches relevant to their characterization. The functional agents (e.g., small molecules or clustered regularly-interspaced short palindromic repeats, CRISPRs) may be developed and investigated either as phenotype perturbagens in combination with other perturbagens for target characterization/validation and/or as prototypes for therapeutics in cell heterogeneous tumors.
All investigators with appropriate expertise and capabilities are encouraged to consider the opportunity regardless of whether or not they participated in the previous issuance of the program.
Visit our Institutionally Limited Submission webpage for updates and other announcements.